Attune Pharmaceuticals has a total of 24 patents globally, out of which 12 have been granted. Of these 24 patents, more than 37% patents are active. The United States of America is where Attune Pharmaceuticals has filed the maximum number of patents, followed by Europe, Australia and Canada. Parallelly, United States of America seems to be the main focused R&D centre and also is the origin country of Attune Pharmaceuticals.
Attune Pharmaceuticals was founded in 2018. Attune Pharmaceuticals is a biotechnology company. The company creates innovative oral small molecule medicines for treating uncommon diseases.
Do read about some of the most popular patents of Attune Pharmaceuticals which have been covered by us in this article and also you can find Attune Pharmaceuticals patents information, the worldwide patent filing activity and its patent filing trend over the years, and many other stats over Attune Pharmaceuticals patent portfolio.
How Many Patents did Attune Pharmaceuticals File Every Year?
Are you wondering why there is a drop in patent filing for the last two years? It is because a patent application can take up to 18 months to get published. Certainly, it doesn’t suggest a decrease in the patent filing.
| Year of Patents Filing or Grant | Attune Pharmaceuticals Applications Filed | Attune Pharmaceuticals Patents Granted |
| 2021 | 1 | 4 |
| 2020 | 1 | 2 |
| 2019 | 8 | 4 |
| 2018 | 2 | 1 |
| 2017 | 1 | 1 |
| 2016 | 5 | – |
| 2015 | 5 | – |
| 2014 | 1 | – |
How many Attune Pharmaceuticals patents are Alive/Dead?
Worldwide Patents
How Many Patents did Attune Pharmaceuticals File in Different Countries?
Countries in which Attune Pharmaceuticals Filed Patents
| Country | Patent |
| United States Of America | 14 |
| Europe | 2 |
| Australia | 2 |
| Canada | 2 |
| Hong Kong (S.A.R.) | 1 |
| Germany | 1 |
| Austria | 1 |
| China | 1 |
Where are Research Centers of Attune Pharmaceuticals Patents Located?
The Research Centers of Attune Pharmaceuticals Patents is the United States of America.
10 Best Attune Pharmaceuticals Patents
US9611252B2 is the most popular patent in the Attune Pharmaceuticals portfolio. It has received 9 citations so far from companies like Lifesci Pharmaceuticals, Janssen Pharmaceutica.
Below is the list of 10 most cited patents of Attune Pharmaceuticals:
| Publication Number | Citation Count |
| US9611252B2 | 9 |
| US10023557B2 | 6 |
| US10301284B2 | 5 |
| US10259803B2 | 4 |
| US20190127366A1 | 4 |
| US10781200B2 | 3 |
| US10266515B2 | 3 |
| US10308637B2 | 2 |
| US20200031799A1 | 1 |
| US20190263818A1 | 1 |
What Percentage of Attune Pharmaceuticals US Patent Applications Were Granted?
Attune Pharmaceuticals (Excluding its subsidiaries) has filed 13 patent applications at USPTO so far (Excluding Design and PCT applications). Out of these 9 have been granted leading to a grant rate of 69.23%.
Below are the key stats of Attune Pharmaceuticals patent prosecution at the USPTO.
Which Law Firms Filed Most US Patents for Attune Pharmaceuticals?
| Law Firm | Total Applications | Success Rate |
| Wilson Sonsini Goodrich & Rosati | 13 | 69.23% |
List of Attune Pharmaceuticals patents
| Attune Pharmaceuticals Patents | Title |
| US11021463B2 | Therapeutic Inhibitory Compounds |
| US10981893B2 | Therapeutic Inhibitory Compounds |
| US10781200B2 | Therapeutic Inhibitory Compounds |
| US9611252B2 | Therapeutic Inhibitory Compounds |
| EP3169325B1 | Therapeutic Inhibitory Compounds |
| CN112770751A | Treatment Of Hereditary Angioedema |
| CA2954814A1 | Isonicotinamide Compounds And Their Use As Plasma Kallikrein Inhibitors |
| CA3092538A1 | Treatment Of Hereditary Angioedema |
| HK40041266A | Treatment Of Hereditary Angioedema |
| US10308637B2 | Therapeutic Inhibitory Compounds |
| US10301284B2 | Therapeutic Inhibitory Compounds |
| US10266515B2 | Therapeutic Inhibitory Compounds |
| US10259803B2 | Therapeutic Inhibitory Compounds |
| US10023557B2 | Therapeutic Inhibitory Compounds |
| US20210395221A1 | Therapeutic Inhibitory Compounds |
| US20200031799A1 | Therapeutic Inhibitory Compounds |
| US20190263818A1 | Therapeutic Inhibitory Compounds |
| US20190127366A1 | Therapeutic Inhibitory Compounds |
| US20200405708A1 | Treatment Of Hereditary Angioedema |
| EP3758702A4 | Treatment Of Hereditary Angioedema |
| AU2015289643B2 | Therapeutic Inhibitory Compounds |
| AU2019227866A1 | Treatment Of Hereditary Angioedema |
| DE602015068752T2 | Therapeutic Inhibitoring Compounds |
| AT1386924T | Therapeutische Hemmende Verbindungen |
What are Attune Pharmaceuticals key innovation segments?
What Technologies are Covered by Attune Pharmaceuticals?
The chart below distributes patents filed by Attune Pharmaceuticals